New aspects in ANCA-associated vasculitides;Aktuelle aspekte ANCA-assoziierter vaskulitiden

Medizinische Klinik

Volumn 99, Issue 9, 2004, Pages 518-522

  Lamprecht, Peter ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ANCA; CD28 T cell; Churg Strauss syndrome; Microscopic polyangiitis; MPO; PR3; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CD28 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; FC RECEPTOR; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL SURFACE; CELLULAR IMMUNITY; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; ENDOTHELIUM CELL; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PATHOGENESIS; REMISSION; REVIEW; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGENS, CD28; AUTOANTIGENS; AZATHIOPRINE; CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MICE; MULTICENTER STUDIES; MYELOBLASTIN; NEUTROPHIL ACTIVATION; PEROXIDASE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, IGG; REMISSION INDUCTION; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALIA;

EID: 4644367496     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-004-1078-6     Document Type: Review

References (50)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
2. Hellmich B, Csernok E, Gross WL. 20 years with ANCA (antineutrophil cytoplasmic autoantibodies): from seromarker to a major pathogenic player in vasculitis. J Leukoc Biol 2003;73:1-2.
3. Lamprecht P, Gross WL. Wegener's granulomatosis. Herz 2004;29:47-56.
4. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
5. Savage COS, Harper L, Holland M. New findings in the pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002;14:15-22.
6. Csernok E, Lüdemann J, Gross WL, et al. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol 1990;137:1113-20.
7. Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990;87:4115-9.
8. Csernok E, Ernst M, Schmitt WH, et al. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994;95:244-50.
9. Reumaux D, De Boer M, Meijer AB, et al. Expression of myeloperoxidase (MPO) in neutrophils is necessary for their activation by anti-neutrophil cytoplasmic autoantibodies (ANCA) against MPO. J Leukoc Biol 2003;73:841-9.
10. Porges AJ, Redecha PB, Kimberly WT, et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994;153:1271-80.
11. Kocher M, Edberg JC, Fleit HB, et al. Antineutrophil cytoplasm antibodies preferentially engage Fc gammaRIIIb on human neutrophils. J Immumol 1998;161:6909-14.
12. Ben-Smith A, Dove SK, Martin A, et al. Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fc-gamma receptor ligation. Blood 2001; 98:1448-55.
13. Williams JM, Ben-Smith A, Hewins P, et al. Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab′)(2) fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J Am Soc Nephrol 2003;14:661-9.
14. Kettritz R, Choi M, Butt W, et al. Phosphatidylinositol 3-kinase controls antineutrophil cytoplasm antibodies-induced respiratory burst in human neutrophils. J Am Soc Nephrol 2002;13:1740-9.
15. Radford DJ, Lord JM, Savage CO. The activation of the neutrophil respiratory burst by antineutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosin kinases and protein kinase C activation. Clin Exp Immunol 1999;118:171-9.
16. Kettritz R, Schreiber A, Luft FC, et al. Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasm antibodies. J Am Soc Nephrol 2001;12:37-46.
17. Choi M, Rolle S, Rane M, et al. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int 2003;63:96-106.
18. Filer AD, Gardner-Medwin JM, Thambyrajah J, et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003;62:162-7.
19. Zänker M, Aries PM, Herlyn K, et al. Accelerated atherosclerosis in Wegener's granulomatosis (WG): a case-control study of arterial wall changes and clinical events. Circulation: submitted.
20. Yang JJ, Preston GA, Alcorta DA, et al. Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA). Kidney Int 2002;62:1638-49.
21. Grimminger F, Hattar K, Papavassilis C, et al. Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med 1996;184:1567-72.
22. Hattar K, Sibelius U, Bickenbach A, et al. Subthreshold concentrations of anti-proteinase 3 antibodies (C-ANCA) specifically prime human neutrophils for fMLP-induced leukotriene synthesis and chemotaxis. J Leukoc Biol 2001;69:89-97.
23. Radford DJ, Luu NT, Hewins P, et al. Antineutrophil antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 2001;44:2851-61.
24. Cockwell P, Brooks CJ, Adu D, et al. Interleukin-8: a pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999;55:852-63.
25. Gross WL, Csernok E, Schmitt WH. Antineutrophil cytoplasmic autoantibodies: immunobiological aspects. Klin Wochenschr 1991;69:558-66.
26. Gross WL. Immunopathogenesis of vasculitis. In: Klippel JH, Dieppe PA, eds. Rheumatology, chapter 7.19, 3rd edn. London: Mosby, 2003:1-8.
27. Reinhold-Keller E, de Groot K, Holl-Ulrich K, et al. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol 2001;19:541-9.
28. Fienberg R. A morphologic and immunohistologic study of the evolution of the necrotizing palisading granuloma of pathergic (Wegener's) granulomatosis. Sem Respir Med 1989;10:126-32.
29. Holl-Urich K, Reinhold-Keller E, Müller A, et al. Pathologie der Vaskulitis: Differential diagnose und ausgewählte Krankheitsbilder. Verh Dtsch Ges Pathol 2002;86:83-90.
30. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al. Persistent carriage of Staphylococcus aureus and relapse rate of Wegener's granulomatosis. Ann Intern Med 1994;120:12-20.
31. Gadola S, Sahly H, Reinhold-Keller E, et al. Nasal carriage of Staphylococcus aureus in patients with Wegener's granulomatosis (WG), rheumatoid arthritis (RA), and polyposis nasi (PN). Sarcoidosis Vasc Diffuse Lung Dis 1997;14:(Suppl 1:29.abstract.
32. Voswinkel J, Müller A, Lamprecht P, et al. Does ANCA formation result from an antigen-triggered immune response in Wegener's endonasal inflamed tissue? Cleve Clin J Med 2002;69-Suppl.2:SII-159. abstract.
33. Pendergraft WF III, Preston GA, Shah RS, et al. Autoimmunity is triggered by cPR-3 (105-201), a protein complementary to human autoantigen proteinase 3. Nat Med 2004;10:72-9.
34. Lamprecht P, Brühl H, Erdmann A, et al. Differences in CCR5 expression on peripheral blood CD4+CD28-T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol 2003;108:1-7.
35. Lamprecht P, Erdmann A, Müller A, et al. Heterogeneity of CD4+ and CD8+ memory T cells in localized and generalized Wegener's granulomatosis. Arthritis Res Ther 2003;5:R25-31.
36. -T-cells are a major source of IFN-γ and TNF-α in Wegener's granulomatosis. Am J Pathol 2002;160:1717-24.
37. Lamprecht P, Müller A, Gross WL. CD28- T cells display features of effector memory T cells in Wegener's granulomatosis [Letter]. Kidney Int 2004;65:1113.
38. Lamprecht P, Moosig F, Csernok E, et al. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 2001;56:751-7.
39. Grunewald J, Halapi E, Wahlström J, et al. T-cell expansions with conserved T-cell receptor β chain motifs in the peripheral blood of HLA-DRB1*0401 positive patients with necrotizing vasculitis. Blood 1998;92:3737-44.
40. Vogt S, Iking-Konert C, Hug F, et al. Shortening of telomeres: evidence for replicative senescence of T cells derived from patients with Wegener's granulomatosis. Kidney Int 2003;63:2144-51.
41. Winek J, Müller A, Csernok E, et al. Frequency of proteinase 3 (PR3)-specific autoreactive T-cells determined by cytokine flow cytometry in Wegener's granulomatosis. J Autoimmun 2004;22:79-85.
42. Kiene M, Csernok E, Müller A, et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001;44:469-73.
43. Jayne D, for the European Vasculitis Study Group (EUVAS). Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001;13:48-55.
44. DeGroot K, Gross WL, Herlyn K, et al. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
45. Jayne D, Rasmussen N, Andrassy K, et al., for the European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil autoantibodies. N Engl J Med 2003;349:36-44.
46. Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666-73.
47. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004;43:315-20.
48. Birck R, Warnatz K, Lorenz HM, et al. 15-deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.
49. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002;41:1303-7.
50. Gause A, Arbach O, Lamprecht P. Der Einsatz von TNFa-Antagonisten bei primär systemischen Vaskulitiden. Z Rheumatol 2003;62:228-34.